In 2020 two randomized placebo-controlled trials were published, testing the efficacy of Sorafenib in inhibiting FLT3-ITD–positive AML recurrence after HCT: SORMAIN in Europe and the study by Xuan et al. Here, FLT3 is linked to acute myeloid leukemia.